ANDREW SEGRAVES: Open Payments
NPI 1487997110 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,139 in 186 payments from 19 companies in 2025. Trend: 2023 $3,579 · 2024 $3,025 · 2025 $3,139
Food & beverage: $3,139
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $481 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $407 |
| Vanda Pharmaceuticals Inc. | 14 | $345 |
| ABBVIE INC. | 17 | $321 |
| E.R. Squibb & Sons, L.L.C. | 22 | $254 |
| Neurocrine BioSciences, Inc. | 14 | $223 |
| Axsome Therapeutics, Inc. | 9 | $151 |
| Lundbeck LLC | 7 | $146 |
| Supernus Pharmaceuticals, Inc. | 8 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $136 |
Products named: REXULTI, CAPLYTA, VRAYLAR, HETLIOZ, COBENFY, INGREZZA, Qelbree, TRINTELLIX.
Industry payments across KS — which companies pay providers there.
